{"nctId":"NCT01391273","briefTitle":"Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis","startDateStruct":{"date":"2011-07-01","type":"ACTUAL"},"conditions":["Eyelash Hypotrichosis"],"count":173,"armGroups":[{"label":"bimatoprost solution 0.03%","type":"EXPERIMENTAL","interventionNames":["Drug: bimatoprost solution 0.03%"]},{"label":"bimatoprost vehicle solution","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: bimatoprost vehicle solution"]}],"interventions":[{"name":"bimatoprost solution 0.03%","otherNames":["LATISSEÂ®"]},{"name":"bimatoprost vehicle solution","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have inadequate eyelashes\n\nExclusion Criteria:\n\n* Any disease/infection/abnormality of the eye or area around the eye\n* Any ocular surgery within 3 months or anticipated need for ocular surgery during the study\n* Any permanent eyeliner or implants of any kind or anticipated use of false eyelashes\n* Any semi-permanent eyelash tint, dye, curl or eyelash extension application within 3 months\n* Use of any over-the-counter eyelash growth product within 6 months or any use of prescription eyelash growth products\n* Use of treatments which may affect hair growth (eg, minoxidil, chemotherapy) within 6 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA)","description":"The investigator evaluated the patient's eyelash prominence using the GEA 4-point scale: 1= minimal, 2= moderate, 3= marked and 4= very marked at Baseline and Month 4. At least a 1-grade increase in the GEA score from Baseline indicated improvement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","spread":null},{"groupId":"OG001","value":"17.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Eyelash Length as Measured by Digital Image Analysis (DIA)","description":"Photographs were taken of the eyelashes and assessed using DIA. Length was measured in millimeters (mm). Data from both eyes were averaged for each participant for analysis. A positive change from Baseline indicated longer length (improvement).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.92","spread":"0.810"},{"groupId":"OG001","value":"7.00","spread":"0.825"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.62","spread":"1.114"},{"groupId":"OG001","value":"-0.04","spread":"0.362"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Eyelash Thickness as Measured by DIA","description":"Photographs were taken of the eyelashes and assessed using DIA. Eyelash thickness (fullness) was assessed across both eyes as an average and is measured in millimeters squared (mm\\^2). A positive change from Baseline indicated fuller eyelashes (improvement).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"0.318"},{"groupId":"OG001","value":"1.01","spread":"0.327"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"0.306"},{"groupId":"OG001","value":"-0.03","spread":"0.195"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Eyelash Darkness as Measured by DIA","description":"Photographs were taken of the eyelashes and assessed using DIA. Eyelash darkness was measured in both eyes and averaged for analysis using a scale where 0=black and 255=white. A negative change from Baseline indicated darker eyelashes (improvement).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"147.57","spread":"20.340"},{"groupId":"OG001","value":"145.27","spread":"18.069"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.02","spread":"10.967"},{"groupId":"OG001","value":"1.38","spread":"10.854"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":87},"commonTop":["Nasopharyngitis"]}}}